The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
COSENTYX (Novartis Pharmaceuticals Australia Pty Ltd)
Product name
COSENTYX
Date registered
Evaluation commenced
Decision date
Approval time
194 (255 working days)
Active ingredients
Secukinumab
Registration type
EOI
Indication
Juvenile Idiopathic Arthritis (JIA)
Enthesitis?Related Arthritis (ERA)
COSENTYX is indicated for the treatment of active enthesitis?related arthritis in patients 4 years and older who have had an inadequate response or were intolerant to at least one NSAID and at least one DMARD.
Juvenile Psoriatic Arthritis (JPsA)
COSENTYX is indicated for the treatment of active juvenile psoriatic arthritis in patients 2 yearsand older who have had an inadequate response or were intolerant to at least one NSAID and at least one DMARD.